Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.urolonc.2020.12.022 http://scihub22266oqcxt.onion/10.1016/j.urolonc.2020.12.022 33451934!7762713!33451934     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Urol+Oncol 2021 ; 39 (4): 213-220 Nephropedia Template TP {{tp|p=33451934|t=2021. Systemic therapy and COVID19: Immunotherapy and chemotherapy |pdf=|usr=}}{{33451934}} gab.com Text Systemic therapy and COVID19: Immunotherapy and chemotherapy JO: Urol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=33451934 #FOAvip As the novel severe acute respiratory syndrome coronavirus-2 related pandemic - Corona Virus Disease 2019 (COVID-19) has emerged, decision making in the context of cancer treatment has become more complex. The apprehension of using drugs that could adversely affect infected patients, the risk of not using life-saving treatments and the complexities related to the type of cancer itself, all must be taken into consideration before proceeding with treatment. Data from large registries such as COVID-19 and Cancer Consortium, Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) and NCI COVID-19 in Cancer Patients Study will hopefully provide granularity on the outcomes of patients with cancer who are infected with COVID-19. As these efforts are underway, this review aims to shed light on the management of patients with genitourinary malignancies being treated with systemic therapies while infected with COVID-19. Twit Text FOAVip Systemic therapy and COVID19: Immunotherapy and chemotherapy ????Urol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=33451934 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33451934 #FOAvip English Wikipedia <ref>{{Cite pmid|33451934}}</ref> Systemic therapy and COVID19: Immunotherapy and chemotherapy #MMPMID33451934 Gulati S; Muddasani R; Gustavo Bergerot P; Pal SK Urol Oncol 2021[Apr]; 39 (4): 213-220 PMID33451934show ga As the novel severe acute respiratory syndrome coronavirus-2 related pandemic - Corona Virus Disease 2019 (COVID-19) has emerged, decision making in the context of cancer treatment has become more complex. The apprehension of using drugs that could adversely affect infected patients, the risk of not using life-saving treatments and the complexities related to the type of cancer itself, all must be taken into consideration before proceeding with treatment. Data from large registries such as COVID-19 and Cancer Consortium, Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) and NCI COVID-19 in Cancer Patients Study will hopefully provide granularity on the outcomes of patients with cancer who are infected with COVID-19. As these efforts are underway, this review aims to shed light on the management of patients with genitourinary malignancies being treated with systemic therapies while infected with COVID-19. |*COVID-19[MESH] |*Neoplasms/drug therapy[MESH] |China[MESH] |Humans[MESH] |Immunotherapy[MESH] |Pandemics[MESH]Systemic therapy and COVID19: Immunotherapy and chemotherapy (epmc).pdf DeepDyve Pubget Overpricing